Repligen Issues $1 Billion of 0.25% Convertible Notes Due 2031
Repligen issued $1.0 billion of 0.25% convertible senior notes due 2031, refinancing part of existing debt and raising additional cash. The offering included $541.4 million exchanged for 2028 notes and $458.6 million sold for cash, with $143.2 million of 2028 notes remaining.
How this was made

The 30-second read
Why it matters
The $1 bn convertible note issuance is a primary corporate action that can affect share price through dilution expectations and balance‑sheet improvement.
Market read
A material financing event for a mid‑cap biotech, likely to move the stock in the short term.
What to watch
Potentially favorable tax treatment of convertible interest and the low coupon rate may make the notes attractive to income investors.
Background
Repligen (RGEN) is a biopharmaceutical company focused on protein purification technologies. The issuance replaces part of its 2028 notes and adds new cash for operations.
Ticker impact
Repligen announced a $1.0 billion issuance of 0.25% convertible senior notes due 2031, refinancing existing debt and raising cash.
likely pressure as the market prices in dilution and higher leverage
Large capital raise of $1 bn is material; convertible feature may convert to equity, creating dilution concerns.
Market effects
May influence other biotech firms' financing trends as convertible debt becomes more attractive.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking biotech financing activity.
Counterpoint
The cash infusion could fund growth initiatives that outweigh dilution concerns, supporting upside.
Key entities
- CompanyRepligen Corp.
Issuer of the convertible senior notes.
- Financial InstitutionU.S. Bank Trust Company
Counterparty facilitating the note issuance.
